Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
Banerjee, S. ; Aghajanian, C. ; Van Nieuwenhuysen, E. ; Santin, A. ; Ring, K. ; Colombo, N. ; Thaker, P. ; Prendergast, E. ; Moore, K. ; Chon, H. S. ... show 10 more
Banerjee, S.
Aghajanian, C.
Van Nieuwenhuysen, E.
Santin, A.
Ring, K.
Colombo, N.
Thaker, P.
Prendergast, E.
Moore, K.
Chon, H. S.
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Banerjee S, Aghajanian C, Van Nieuwenhuysen E, Santin A, Ring K, Colombo N, et al. Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2024 OCT;34(SUPPL_3):A13-A. PubMed PMID: WOS:001444792200025. English.